Related references
Note: Only part of the references are listed.Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability
Eric Lespessailles
JOINT BONE SPINE (2013)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cost-Effectiveness of Fracture Prevention in Men Who Receive Androgen Deprivation Therapy for Localized Prostate Cancer
Kouta Ito et al.
ANNALS OF INTERNAL MEDICINE (2010)
Efficacy and safety of monthly ibandronate in men with low bone density
Eric S. Orwoll et al.
BONE (2010)
The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study
T. W. O'Neill et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Incidence of clinically diagnosed vertebral fractures: A population-based study in rochester, minnesota, 1985-1989
Cyrus Cooper et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Efficacy and Safety of a Once-Yearly i.v. Infusion of Zoledronic Acid 5 mg Versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study
Eric S. Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study
Steven Boonen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial
S. Aubrey Stoch et al.
JOURNAL OF RHEUMATOLOGY (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Osteoporosis in men
Peter R. Ebeling
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A population-based assessment of rates of bone loss at multiple skeletal sites: Evidence for substantial trabecular bone loss in young adult women and men
B. Lawrence Riggs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Early and rapid bone mineral density loss of the proximal femur in men
Peter Nordstrom et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Bone fragility in men - where are we?
E. Seeman et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men
Howard A. Fink et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
JD Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Effects of sex and age on bone microstructure at the ultradistal radius: A population-based noninvasive in vivo assessment
S Khosla et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Effect of testosterone replacement on trabecular architecture in hypogonadal men
M Benito et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women
AM Sawka et al.
BMC MUSCULOSKELETAL DISORDERS (2005)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
JM Kaufman et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study
BA Mohr et al.
CLINICAL ENDOCRINOLOGY (2005)
Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo osteoporosis epidemiology study
KP Chang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The importance of bisphosphonate therapy mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]
ES Kurland et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden
F Borgström et al.
BONE (2004)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
E Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer
RW Ross et al.
JOURNAL OF UROLOGY (2002)
Biochemical markers of bone turnover in men
P Szulc et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men
C Wang et al.
CLINICAL ENDOCRINOLOGY (2001)
Bone turnover markers and sex hormones in men with idiopathic osteoporosis
P Pietschmann et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2001)
Alendronate for the treatment of osteoporosis in men
E Orwoll et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
